Warne 2015 J Biol Chem: Difference between revisions
(Created page with "{{Publication |title=Warne J, Pryce G, Hill J, Shi X, LennerΓ₯s F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D...") Β |
|||
Line 21: | Line 21: | ||
}} | }} | ||
== Clarification == | == Clarification == | ||
*Baker D refers to David Baker of Queen Mary University of London and not [[Baker D|Daniel Baker] of the University of Auckland | *Baker D refers to David Baker of Queen Mary University of London and not [[Baker D|Daniel Baker]] of the University of Auckland |
Revision as of 12:47, 16 February 2016
Warne J, Pryce G, Hill J, Shi X, LennerΓ₯s F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D, Selwood D (2015) Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis. J Biol Chem [Epub ahead of print]. |
Warne J, Pryce G, Hill J, Shi X, Lenneraas F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D*, Selwood D (2015) J Biol Chem
Abstract: The mitochondrial permeability transition pore (PT pore) is a recognised drug target for neurodegenerative conditions such as multiple sclerosis (MS) and for ischaemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, ppif) is a positive regulator of the pore and genetic downregulation or knockout improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off target effects, immune-suppression and toxicity. We therefore designed and synthesised a new mitochondrially-targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine (CsA). X-ray analysis was used to validate the design concept and biological evaluation revealed selective cellular inhibition of CypD and the PT pore with reduced cellular toxicity compared to CsA. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis (MS), JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use. β’ Keywords: EAE, X-ray crystallography, Cyclophilin D, Cyclosporin, Mitochondrial permeability transition (MPT), Mitochondrial targeting, Multiple sclerosis, Neurodegeneration, Neurodegenerative disease
β’ O2k-Network Lab: UK London Duchen MR
Labels: MiParea: Respiration, mt-Membrane
Pathology: Neurodegenerative
Organism: Mouse Tissue;cell: Liver
Regulation: Inhibitor
Coupling state: LEAK, OXPHOS, ETS"ETS" is not in the list (LEAK, ROUTINE, OXPHOS, ET) of allowed values for the "Coupling states" property.
HRR: Oxygraph-2k
Labels, [Epub ahead of print], 2016-01
Clarification
- Baker D refers to David Baker of Queen Mary University of London and not Daniel Baker of the University of Auckland